Abstract:Background: Metastatic esophagogastric cancers (EGCs) have a poor prognosis with an approximately 5% 5-year survival. Additional treatment approaches are needed. c-MET gene-amplified tumors are an uncommon but potentially targetable subset of EGC. Clinical characteristics and outcomes were evaluated in patients with MET-amplified EGC and compared with those without MET amplification to facilitate identification of these patients and possible treatment approaches. Patients and methods: Patients with locally advanced or metastatic MET-amplified EGC at Massachusetts General Hospital (MGH) were identified using fluorescent in situ hybridization analysis, with a gene-to-control ratio of ≥2.2 defined as positive. Non-MET-amplified patients identified during the same time period who had undergone tumor genotyping and treatment at MGH were evaluated as a comparison group. Results: We identified 233 patients evaluated for MET amplification from 2002 to 2019. MET amplification was seen in 28 (12%) patients versus 205 (88%) patients without amplification. Most MET-amplified tumors occurred in either the distal esophagus (n = 9; 32%) or gastroesophageal junction (n = 10; 36%). Of MET-amplified patients, 16 (57%) had a TP53 mutation, 5(18%) had HER2 co-amplification, 2 (7.0%) had EGFR co-amplification, and 1 (3.5%) had FGFR2 co-amplification. MET-amplified tumors more frequently had poorly differentiated histology (19/28, 68.0% vs. 66/205, 32%; p = .02). Progression-free survival to initial treatment was substantially shorter for all MET-amplified patients (5.6 vs. 8.8 months, p = .026) and for those with metastatic disease at presentation (4.0 vs. 7.6 months, p = .01). Overall, patients with MET amplification had shorter overall survival (19.3 vs. 24.6 months, p = .049). No difference in survival was seen between low MET-amplified tumors (≥2.2 and <25 MET copy number) compared with highly amplified tumors (≥25 MET copy number). Conclusion: MET-amplified EGC represents a distinct clinical entity characterized by rapid progression and short survival. Ideally, the identification of these patients will provide opportunities to participate in clinical trials in an attempt to improve outcomes. Implications for practice: This article describes 233 patients who received MET amplification testing and reports (a) a positivity rate of 12%, similar to the rate of HER2 positivity in this data set; (b) the clinical characteristics of poorly differentiated tumors and nodal metastases; and (c) markedly shorter progression-free survival and overall survival in MET-amplified tumors. Favorable outcomes are reported for patients treated with MET inhibitors. Given the lack of published data in MET-amplified esophagogastric cancers and the urgent clinical importance of identifying patients with MET amplification for MET-directed therapy, this large series is a valuable addition to the literature and will have an impact on future practice.

Precision Treatment Paradigm: Genomic Features and Therapeutic Implications in Mesenchymal‐epithelial Transition‐amplified Gastric Cancer

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer

Peer Review #2 of "TP53 Mutation and MET Amplification in Circulating Tumor DNA Analysis Predict Disease Progression in Patients with Advanced Gastric Cancer (V0.1)"

Profiling genomic characteristics related to immunotherapy for gastric cancer with amplified MET .

HER2, MET and FGFR2 Oncogenic Driver Alterations Define Distinct Molecular Segments for Targeted Therapies in Gastric Carcinoma.

Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1

Cmet As A Potential Therapeutic Target In Gastric Cancer

Comprehensive Profiling of MDM2/TP53 Genomic Aberration in Chinese Patients with Diverse Malignancies.

P-053 MET Overexpression and Amplification Define a Distinct Molecular Subgroup for Targeted Therapies in Gastric Cancer

Pulmonary Lymphangitis Carcinomatosis: A Peculiar Presentation Clustering in MET‐amplified Gastric Cancer

Comprehensive analysis of <i>MET</i> mutations in NSCLC patients in a real-world setting

Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers

Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer

Integration of transcriptomics, proteomics, and metabolomics data to reveal HER2-associated metabolic heterogeneity in gastric cancer with response to immunotherapy and neoadjuvant chemotherapy

Matched Therapies for Advanced Gastric Cancer Based on Genotype: A Real-World Study in China.

Mesenchymal-epithelial transition factor amplification correlates with adverse pathological features and poor clinical outcome in colorectal cancer

Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer

Genomic characterization of Chinese locally advanced or metastatic gastric cancer.

Identifying mitophagy-related genes as prognostic biomarkers and therapeutic targets of gastric carcinoma by integrated analysis of single-cell and bulk-RNA sequencing data